Marapharm Ventures Inc (OTCMKTS:MRPHF) has signed a letter of intent to take over Full Spectrum Medicinal Inc. The company has set September 30, 2018, as the deadline to conduct due diligence on Full Spectrum and complete the acquisition.

Following the takeover, Marapharm Ventures will merge Full Spectrum application with Health Canada Application. It helps to become a licensed cannabis manufacturer of premium flower for commercial use. The company will be able to deliver organic and quality cannabis products in a cost-effective way and boost profits.

The business model of the company is to build standardized engineered bio-secure facilities. The state of the art facilities are scalable and saves energy and promote cost-effective cultivation. The company will be able to grow quality cannabis indoors at reduced costs. Marapharm Ventures will deliver the first assembly building at an approved site situated near the Salmon Arm, British Columbia.

The company is planning for penetration of the legal cannabis with edibles, oils, and flowers and build a long-term value in the rapidly growing market.

Canada Legalizes Marijuana

Justin Trudeau, Prime Minister, Canada has announced the legalization of marijuana on June 20, 2018. The legalization of marijuana comes into effect from October 17, 2018. It has put an end to the prohibition of cannabis in Canada.

Marapharm Ventures Inc Issues an Update on Market Activities to The Shareholders As Frankfurt’s Clearstream Closes Doors to The North American cannabis stocks

Marapharm Ventures Inc has issued an update on the recent market activities to the shareholders on the backdrop of Frankfurt’s Clearstream shutting the doors to North American Cannabis stocks.

Frankfurt, Germany based major central securities depository – Clearstream has set June 29, 2018, as the deadline as for final settlements free of fee. However, Clearstream will offer the services till September 28, 2018, and after that it will not settle the securities related to cannabis and narcotic products due to legal reasons.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has submitted its Marketing Authorization Application to the European Medicines Agency for Epidiolex® as adjunctive treatment for seizures related with Dravet syndrome and Lennox-Gastaut syndrome, two extremely treatment-resistant types of childhood-onset epilepsy.

The details

GW Pharmaceuticals has obtained Orphan Designations from the European Medicines Agency for Epidiolex for the cure of Dravet syndrome, LGS, and lately, West syndrome & Tuberous Sclerosis Complex. In October 2017, the company completed the filing of its rolling Epidiolex NDA to the United States FDA, also for seizures linked with Dravet syndrome and LGS. This NDA has been approved by the FDA for Priority Review.

Justin Gover, the CEO of GW Pharmaceuticals, expressed that this Marketing Authorization Application filing marks another key milestone for the Epidiolex plan and is a vital next step toward offering this prospective new treatment option internationally. The company is dedicated to making Epidiolex available to people in Europe that fight with the burden of living with Dravet syndrome and LGS, both extremely difficult to cure and devastating conditions. They continue to establish a commercial infrastructure in Europe in expectation of future approval and release.

The MAA filing for Epidiolex is supported by report from three Phase III efficacy and safety trials, each of which fulfilled their primary objective. Epidiolex was usually well tolerated in these studies. The MAA comprises safety data on around 1,500 patients, with around 400 people on continuous therapy for over one year. Around 26% of the people suffering from Epidiolex from the Phase III pivotal plan came from European sites. Beyond pivotal efficacy and safety data, the MAA comprises a comprehensive clinical pharmacology, toxicology and pre-clinical package.

In unrelated news, the GW Pharmaceuticals posted that the U.S. FDA has accepted its filing for Priority Review of its New Drug Application for Epidiolex®. The PDUFA goal date for FDA completion is June 27, 2018.

In the last trading session, the stock price of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) closed marginally in green, indicating that the stock may attempt to recoup its last week losses. Earlier in October, the company reported that it has closed the rolling submission of a NDA to the USFDA for Epidiolex® as adjunctive treatment targeting seizures associated with LGS and Dravet syndrome. This task was closed along with the help of company’s subsidiary unit – Greenwich Biosciences.

The details

GW Pharmaceuticals has been granted with Rare Pediatric Disease as well as Orphan Drug Designations from the USFDA for Epidiolex in the treatment of Dravet syndrome and LGS. Additionally, it has been given Fast Track Designation from the USFDA for Epidiolex for the cure of Dravet syndrome. Justin Gover, the Chief Executive Officer of GW Pharmaceuticals, expressed that the filing of the Epidiolex NDA is a significant achievement for people suffering with LGS and Dravet syndrome.

This indicates that there is a potentially new treatment option in horizon for these two difficult to treat and grave conditions. On behalf of company’s employees, patients and clinicians, who have been a part of the Epidiolex plan, they are pleased to file the NDA for this promising therapy for U.S. FDA review. The team look forward to offer every support to the FDA throughout the assessment course. This regulatory submission is an indication of GW’s commitment to developing unique cannabinoid-based treatments. The company is currently assessing additional clinical development plans in other orphan seizure disorders.

The NDA for Epidiolex goes with on the back of data from three Phase III safety and efficacy trials, each of which achieved their main endpoint. GW Pharmaceuticals intends to file a Marketing Authorization Application in Europe for Epidiolex in the imminent future. Epidiolex is a pharmaceutical formulation of purified CBD, which is in development for the cure of numerous rare childhood-onset epilepsy ailments.

The stock of SinglePoint, Inc (OTCMKTS:SING) closed at $0.073 losing 8.25% in yesterday’s trading session. This provider has recently been seen to pay much focus to accelerated growth in Cannabis sector and it targets to make its impact felt globally.

One of its greatest moves has been the signing of a letter of intent in which it expressed its interest towards the acquisition of Dr. FeelGood. This is a rather profitable medical marijuana distribution that has for pretty long indicated its commitment to setting up a proprietary delivery and ordering technology. SinglePoint remains optimistic that the new acquisition will help towards boosting it revenue stream.

The provider is confident of closing this acquisition soon and that will give a proper demonstration of the company’s ability to develop its portfolio of investments in established high-growth, high-potential cannabis enterprises. Earlier this year, this company succeeded in the acquisition of some two companies and asserts that the latest acquisition will be a significant addition to its portfolio.

SinglePoint CEO, Greg Lambrecht opined, “We are well capitalized to continue acquisitions and we are optimistic to complete around three more acquisitions and significantly increase the company’s revenue.”

He added that the company was in a better position, something that they have been looking forward to for quite long.

The President of Dewmar International BMC Inc (OTCMKTS:DEWM), J.D. Houston has expressed his willingness to attend the upcoming conference. The MJAC 2017 will be providing the various retail investors with a perfect opportunity to access crucial business insight on firms in the cannabis sector.

The shareholders that will be attending the meeting will learn much regarding Dewmar’s cannabis business setup from revenue generating services and products to portfolio of IP assets. The president is also expected to have a word with managers of micro-cap funds who have indicated their interest towards investing in firms like Dewmar.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) recently gave its latest update on the Q3 2017 Financial Performance. The NDA filing procedure for Epidiolex is already up and running and most probably by October the final sections of the filing will be at the verge of completion.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) happens to be a biopharmaceutical provider focusing on the discovery, development as well as the commercialization of a wide spectrum of therapeutics from its proprietary cannabinoid product platform.

The company through one of its top executives has come forward to make public American Academy of Neurology (AAN)’s issuance of the positive results associated with a second Phase 3 study (GWPCARE3) of Epidiolex® (cannabidiol or CBD) among adults and children as well who are struggling with Lennox-Gastaut syndrome (LGS).

According to some close sources, the data will most probably be presented during the forthcoming meeting linked with the American Academy of Neurology (AAN) situated in Boston, MA. The announcement from a speculative point of view is sure to put a smile on the faces of the large number of patients struggling with related complications.

As a matter of fact, the Lennox-Gastaut syndrome happens to be one of the trickiest types of epilepsy for medical experts to deal with. It was disclosed from the placebo-controlled research that indeed Epidiolex is observed to clinically provide significant reductions in an acceptable safety and tolerability profile in line with the seizure frequency.

According to one of the provider’s top executives, Epidiolex has the capacity to offer a positive change towards dealing with LGS .On that same note, he moved ahead to show his great excitement following the plans the company had put in place in the future prescriptions.

It goes without saying that what any top company needs to ensure is the setting up of a more standardized as well as a tested pharmaceutical formulation of cannabidiol. That will help a huge deal towards helping patients around the globe.

The trial set up revealed that indeed Epidiolex was from a general perspective well tolerated. However, the recent Phase 3 Study had showcased a pattern of some adverse events that had remained quite persistent over time.

It was a great thing that during a prestigious meeting there was the highlighting of the Phase 3 epilepsy program, and that the wide neurological community needed to pay closer attention as a matter of fact!

GW Pharmaceuticals Plc (NASDAQ:GWPH) has announced its bringing on board Scott Giacobello to serve in the capacity of the Chief Financial Officer. The company through its cannabinoid product platform has over the years engaged in the discovery, development as well as commercialization of novel products and still hopes to do much more in years to come towards promoting good health around the globe.

The company’s headquarters in the U.S are located in Carlsbad, California and this is where the new top official will be based. He will be reporting to the leading company’s Chief Executive Officer Justin Gover and during this appointment all eyes are focused on him to see what value and contribution he brings to the company.

Some time back, there was a growing need for the company to set up a new executive role. In line with Scott Giacobello’s appointment was the appointment Adam George, to serve in the capacity of Managing Director UK. The newly established role had a wide array of responsibilities linked to UK operations. This official was and still continues to be answerable to GW’s Chief Executive Officer Justin Gover.

Justin Gover lately made some remarks stating that the company is headed towards a promising future even by the look of the appointments it has been making lately. He termed them important leadership appointments which happen to be an on-point reflection of what the company has grown to become in the direction of evolving to become a significant transatlantic commercial-stage biopharmaceutical provider.

At the moment, the company awaits the Epidiolex approval and launch as well and according to the top executive; it is a good thing that the company is listed on NASDAQ. As an organization, they are prepared to make the transition from being a Foreign Private Issuer reporting under IFRS to moving a notch-higher to be the domestic registrant reporting and this will be under the umbrella of the US GAAP.

Giacobello boasts of a wealth of experience after working in a number of top positions. However, the latest have been his serving at Black and Decker Corporation not of course forgetting Ernst and Young. He happens to be a Certified Public Accountant and a proud holder of a bachelor’s degree in business administration which he obtained from University of Notre Dame.

While we are still talking about MMJ companies, a micro cap company that needs mention is American Premium Water (HIPH). As per today’s press release, the company is looking forward to launch its CBD-water. “We are excited to be increasing our reach in the most sought out industry in America. CBD is a non-psychoactive byproduct of the hemp plant, widely believed to have numerous health benefits. As a Naturalist, I feel that our customers deserve to live a healthy lifestyle,” said Founder Alfred T. Culbreth. Click HERE to read more on HIPH.